Methyl-β-cyclodextrin Enhances Tumor Cellular Uptake and Accumulation of Α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles.

Meiqi Xu,Junwei Liu,Jianming Yu,Jingwen Wang,Hui Li,Ting Zhong,Yanli Hao,Zhuoyue Li,Jingru Wang,Xu Huang,Hui Wang,Yubo Tian,Heng Zhao,Qingchao Wei,Xuan Zhang

DOI: https://doi.org/10.1021/acs.molpharmaceut.4c00190

2024-01-01

Molecular Pharmaceutics

Abstract:Improving nanomedicine uptake by tumor cells is key to achieving intracellular drug delivery. In this study, we found that methyl-β-cyclodextrin (MβCD) can significantly promote the intracellular accumulation of nanoparticulated α-linolenic acid-paclitaxel conjugates (ALA-PTX NPs) via enhanced clathrin-mediated endocytosis and limited degradation in lysosomes. Our in vitro results indicated that MβCD not only reduced the plasma membrane cholesterol content and increased plasma membrane fluidity, leading to ALA-PTX NPs being more easily incorporated into the plasma membrane, further enhancing membrane fluidity and making the plasma membrane more susceptible to tensile deformation, forming intracellular vesicles to enhance ALA-PTX NP cellular uptake, but also destroyed lysosomes and then limited ALA-PTX NPs' degradation in lysosomes. In HepG2 tumor-bearing mice, MβCD was also able to enhance the antitumor activity of ALA-PTX NPs in vivo. Moreover, we found that MβCD specifically promoted PUFA-paclitaxel conjugate NP cellular uptake. The cellular uptake of PTX liposome which shares an endocytosis pathway with ALA-PTX NPs could be enhanced by MβCD combined with ALA or ALA-PTX NPs. Therefore, we suggested that MβCD combined with polyunsaturated fatty acid-conjugation would be an effective strategy for improving intracellular delivery of nanoparticulated chemotherapeutic drugs used for combination administration to enhance antitumor efficiency.